Serum visfatin characteristic peak screening coronary heart disease study based on Raman spectroscopy

This study used Raman spectroscopy to explore differences between serum visfatin and its subcomponents in healthy people and coronary heart disease (CHD) patients. To explore whether serum visfatin can be used as screening biomarker for CDH. In total, 60 CHD patients and 57 healthy people were enrolled from Xinjiang Production and Construction Corps Seventh Division Hospital. Serum samples were collected and detected by Raman spectroscopy, and the characteristic peaks of serum visfatin were analyzed. The spectral peaks analysis showed, the peaks at 850.95, 1265.92, 1336.99, 1446.48, 1603.83, and 1657.69 cm −1 were stronger in the CHD patient sample, and the spectral peaks at 1000.52, 1154.51, and 1515.53 cm −1 were stronger in the healthy sample. Clinical sample verification revealed that the 1265.92 and 1446.48 cm −1 peaks had certain distinguishing effects on CHD patients and healthy people.